Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safety profile of extended-release niacin in the AIM-HIGH trial.

Literature DB >> 25014706

Safety profile of extended-release niacin in the AIM-HIGH trial.

Todd J Anderson¹, William E Boden, Patrice Desvigne-Nickens, Jerome L Fleg, Moti L Kashyap, Ruth McBride, Jeffrey L Probstfield.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 25014706 PMCID： PMC4156937 DOI： 10.1056/NEJMc1311039

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

3 in total

1. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors: William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal: N Engl J Med Date: 2011-11-15 Impact factor: 91.245

2. Effects of extended-release niacin with laropiprant in high-risk patients.

Authors: Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage
Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245

3. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

Authors:
Journal: Eur Heart J Date: 2013-02-26 Impact factor: 29.983

3 in total

15 in total

1. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.

Authors: Manik Chhabra; Kota Vidyasagar; Sai Krishna Gudi; Jatin Sharma; Rishabh Sharma; Muhammed Rashid
Journal: PLoS One Date: 2022-07-01 Impact factor: 3.752

Review 2. Targeting ApoC-III to Reduce Coronary Disease Risk.

Authors: Sumeet A Khetarpal; Arman Qamar; John S Millar; Daniel J Rader
Journal: Curr Atheroscler Rep Date: 2016-09 Impact factor: 5.113

Review 3. Vitamin paradox in obesity: Deficiency or excess?

Authors: Shi-Sheng Zhou; Da Li; Na-Na Chen; Yiming Zhou
Journal: World J Diabetes Date: 2015-08-25

4. A pilot study of the effects of niacin administration on free fatty acid and growth hormone concentrations in children with obesity.

Authors: O A Galescu; M K Crocker; A M Altschul; S E Marwitz; S M Brady; J A Yanovski
Journal: Pediatr Obes Date: 2016-09-21 Impact factor: 4.000

5. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.

Authors: Ronald B Goldberg; Vera A Bittner; Richard L Dunbar; Jerome L Fleg; George Grunberger; John R Guyton; Lawrence A Leiter; Ruth McBride; Jennifer G Robinson; Debra L Simmons; Carol Wysham; Ping Xu; William E Boden
Journal: Am J Med Date: 2016-03-29 Impact factor: 4.965

Safety profile of extended-release niacin in the AIM-HIGH trial.

1. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

2. Effects of extended-release niacin with laropiprant in high-risk patients.

3. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

1. Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.

Review 2. Targeting ApoC-III to Reduce Coronary Disease Risk.

Review 3. Vitamin paradox in obesity: Deficiency or excess?

4. A pilot study of the effects of niacin administration on free fatty acid and growth hormone concentrations in children with obesity.

5. Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.

Review 6. Current therapies for lowering lipoprotein (a).

7. HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack.

Review 8. Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens.

9. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials.

10. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.